SCD and type 2 diabetes mellitus: Secondly, as SCD1 inhibitor MK-8245 for the treatment of type II diabetes had been done in the clinical trial (NCT00790556) and relevant results revealed that no serious adverse events occurred in all patients evaluated [28].